Muscle Pharm Corporation (OTC:MSLP) is on the way down again. After a few days of positive price changes, yesterday the MSLP_chart1.pngstock lost almost 4% of its price, while its traded volume rose up.

Looks like even the good news doesn’t help MSLP to hold the climb, thus the company tried another well-known strategy – promotions. In fact, the promotional campaign has been on since April 11, though it hasn’t been much helpful. Nevertheless, the stock alerts continue struggling to fuel up MSLP stock price.

The positive news hasn’t stopped either. Throughout the whole campaign, Muscle Pharm has been publishing optimistic announcements on its business to attract investors. Yesterday, the company made another announcement to report that it was to attend the largest international health and fitness trade-show in the world on April 13-17 in Germany. According to Brad Pyatt, CEO of MSLP, this show was a great opportunity for meeting customers internationally.

Apparently, the positive news along with the on-going promotions aimed to impress traders and pump up MSLP stock price, however, it still doesn’t look stable enough. It is just a matter of time for the final results to be seen.

MusclePharm Corporation is a development-stage company that markets sports nutrition products for athletes, body builders and health-minded individuals. The April campaign of MSLP is held by Penny Stock Circle and the usual paying party remains Red Rock Marketing, which has paid $50.000 so far for the encouraging stock alerts.[BANNER]

Muscle_Pharm.pngAt the same time, the annual results of Muscle Pharm still look discouraging. By December 31, 2010 liabilities of Muscle Pharm were 50% higher than its total assets and the accumulated stockholders’ deficit was higher than $1 million. Meanwhile, the total accumulated deficit of MSLP reached $21 million, not considering the other huge losses.

Today, MSLP announced that Mr. Pyatt, the CEO of the company,  has beneficial ownership of 13.27% of the total issued and outstanding shares of Muscle Pharm. However, neither Mr. Pyatt, not the rest of the management are able to cover the company’s liabilities as well as the increasing losses.